Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Zanolimumab

Generic Name: Zanolimumab

Drug Type: Biotech

CAS Number: 652153-01-0

Unique Ingredient Identifier: HG3L8885M0

Overview

Zanolimumab is a fully human monoclonal antibody directed against CD4.

Background

Zanolimumab is a fully human monoclonal antibody directed against CD4.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

Phase 2

Terminated

Posted: 2010/07/12

Sponsor:National Cancer Inst...

ID:NCT01160445

Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

Phase 3

Terminated

Posted: 2005/08/09

Sponsor:

Emergent Product Dev...

ID:NCT00127881

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Phase 2

Completed

Posted: 2003/10/15

Sponsor:Genmab

ID:NCT00071071

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Phase 2

Completed

Posted: 2003/10/15

Sponsor:Genmab

ID:NCT00071084

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

Phase 2

Terminated

Posted: 2002/08/01

Sponsor:Genmab

ID:NCT00042406

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy